SEC Form 4 · accession 0000899243-19-002533
BIODELIVERY SCIENCES INTERNATIONAL INC · BDSI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Francis E Odonnell Jr.
Director
Period of report
Jan 31, 2019
Accepted (ET)
Feb 4, 2019 · 7:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001103021
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Feb 1, 2019 | S | 8,000 | $4.60 | D | 498,187 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares of Common Stock were automatically sold under a pre-planned 10b5-1 trading plan.
- F2The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
- F3On February 1, 2019, the Reporting Person sold an aggregate of 8,000 shares of the Issuer's Common Stock at a weighted average price of $4.60 per share. The highest sale price for the Common Stock was $4.68 per share and the lowest sale price was $4.52 per share.